Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Jalosome® Soothing Gel Efficacy Grade 2 or 3 Radiodermatitis.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04692389
Recruitment Status : Not yet recruiting
First Posted : December 31, 2020
Last Update Posted : January 5, 2021
Sponsor:
Collaborator:
Oncology Institute of Southern Switzerland
Information provided by (Responsible Party):
Welcare Industries SpA

Brief Summary:

Testing the efficacy of the Jalosome® Soothing gel in 2 or 3 grade radiodermatitis healing in oncological patients.

The investigators would like to know also the efficacy of the device on quality of life and pain.


Condition or disease Intervention/treatment Phase
Radiodermatitis Oncology Quality of Life Pain Device: Jalosome soothing gel Not Applicable

Detailed Description:

The overall objective of the study is to evaluate the efficacy of the class IIA medical device Jalosome® soothing gel in the healing of grade 2 or 3 radiodermatitis, in oncology patients undergoing radiotherapy treatment, during a 8-week observation period.

The secondary endpoints are radiodermatitis pain control and quality of life.

The investigators would like to involve 30 oncology patients. All oncology diagnosis will be included in this pilot study. The study will adopt a quasi-experimental design with one arm. The results will be used to determine the sample size for a clinical trial in which the class IIA medical device Jalosome® soothing gel will be compared to usual care.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:

The investigators would like to involve 30 oncology patients with 2 or 3 grade radiodermatitis (based on RTOG score).

All oncology diagnosis will be included.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Efficacy of the Medical Device Jalosome® Soothing Gel in the Healing of Grade of 2 or 3 Radiodermatitis, Pain Intensity Reduction, as Well as Improvement of QoL in Oncology Patients: a Pilot Study.
Estimated Study Start Date : February 1, 2021
Estimated Primary Completion Date : February 1, 2023
Estimated Study Completion Date : March 31, 2023

Arm Intervention/treatment
Experimental: Jalosome® Soothing gel

The medical device will be applied by the patient himself, after appropriate training carried out by the nurse, twice a day, in the quantity necessary to cover the lesion (0.2g of gel /16 cm2 of skin (one spray), repeated as many times as necessary to cover the entire lesion). The treatment will last 8 weeks.

The medical device will be delivered in the quantity strictly necessary to carry out the therapies between visits, in order to monitor its use. Patients will be seen weekly by the nurse, in order to ensure the best continuity of care and promote adherence to the study. Patients will be asked to keep a weekly diary, in which they will report their level of pain, analgesic therapy and medication. Nurses will be available for telephone counselling, if necessary.

Device: Jalosome soothing gel
This study has not got other intervention
Other Name: No other intervention




Primary Outcome Measures :
  1. Grade 2 or 3 radiodermatitis healing [ Time Frame: 8 weeks ]

    The primary endpoint is the number of grade 2 or 3 radiodermatitis healed by the application of Jalosome® soothing gel during the observation period, out of the total number of patients treated. This endpoint will be assessed by photographic documentation of lesion improvement and healing and with the aid of the RGOT scale (which should regress from grade 2 or 3 to grade 0 or 1).

    The time to regression of the lesion will also be monitored on this same endpoint in order to establish the rate of efficacy of the product against grade 2 and 3 lesions.



Secondary Outcome Measures :
  1. Pain quality and intensity [ Time Frame: 8 weeks ]
    The first secondary endpoint will be the intensity and quality of pain, measured respectively by the NRS scale and by questions on the type of pain perceived (twinge, burning, pins, allodynia (i.e. a painful impulse following a harmless stimulus), cramp-like, piercing (stab-like)).

  2. Skindex questionnaire - 16 for quality of life [ Time Frame: at the beginning, after 4 weeks and after 8 weeks ]
    Quality of life will then be assessed as a second enpoint, using the Skindex questionnaire - 16



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged ≥18 years
  • Patients with cancer* undergoing radiotherapy treatment
  • Patients with grade 2 or 3 radiotherapy lesions who are naive to radiodermatitis treatment or unresponsive to previous treatment
  • Patients who have given written informed consent
  • Patients expected to be followed at the centre for at least 8 weeks
  • Patients with Karnofsky Performance Status(KPS) scale ≥ 40

Exclusion Criteria:

  • Patients with grade 1 and grade IV radiodermatitis
  • Patients with known intolerance to the components in Jalosome® soothing gel
  • Patients who have already received radiotherapy in the past on the irradiated area
  • Patients with cognitive impairment that does not allow adequate compliance with the protocol
  • Patients with brain metastases
  • Pregnant or lactating patients
  • Patients with KPS < 40

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04692389


Locations
Layout table for location information
Switzerland
Oncology Institute Of Southern Switzerland -radio oncology unit
Bellinzona, Canton Ticino, Switzerland, 6501
Contact: Loris Bonetti    +41918118957    loris.bonetti@eoc.ch   
Contact: Giovanni Presta    +41918118132    giovanni.presta@eoc.ch   
Sub-Investigator: Andrea Puliatti         
Sub-Investigator: Dario Valcarenghi         
Sub-Investigator: Angela Tolotti         
Sub-Investigator: Francesco Martucci         
Sub-Investigator: Davide Sari         
Sponsors and Collaborators
Welcare Industries SpA
Oncology Institute of Southern Switzerland
Layout table for additonal information
Responsible Party: Welcare Industries SpA
ClinicalTrials.gov Identifier: NCT04692389    
Other Study ID Numbers: Welcare 012020
First Posted: December 31, 2020    Key Record Dates
Last Update Posted: January 5, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Welcare Industries SpA:
radiodermatitis
oncology
quality of life
pain
wound healing
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Radiodermatitis
Dermatitis
Skin Diseases
Radiation Injuries
Wounds and Injuries